» Articles » PMID: 19422869

SiRNA Delivery Systems for Cancer Treatment

Overview
Specialty Pharmacology
Date 2009 May 9
PMID 19422869
Citations 168
Authors
Affiliations
Soon will be listed here.
Abstract

With increasing knowledge on the molecular mechanisms of endogenous RNA interference, small interfering RNAs (siRNAs) have been emerging as innovative nucleic acid medicines for treatment of incurable diseases such as cancers. Although several siRNA candidates for the treatment of ocular and respiratory diseases are undergoing clinical trials, there are challenges inherent in the further development of siRNAs for anti-cancer therapeutics, because systemic administration will be required in most cases. In addition to nonspecific off-target and immune stimulation problems, appropriate delivery remains a major hurdle. The technologies developed for delivery of nucleic acid medicines such as plasmid DNA and antisense oligonucleotides have paved the way to rapid progress for in vivo delivery of siRNAs. Here, we review various in vivo delivery strategies including chemical modification, conjugation, lipid-based techniques, polymer-based nanosystems, and physical methods. Moreover, the current progress in siRNA delivery systems for gynecologic, liver, lung, and prostate cancers is discussed.

Citing Articles

Nucleic acid functionalized extracellular vesicles as promising therapeutic systems for nanomedicine.

Liu C, He D, Cen H, Chen H, Li L, Nie G Extracell Vesicles Circ Nucl Acids. 2024; 3(1):14-30.

PMID: 39697871 PMC: 11648500. DOI: 10.20517/evcna.2021.21.


Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges.

Ubanako P, Mirza S, Ruff P, Penny C Front Mol Biosci. 2024; 11:1447953.

PMID: 39355533 PMC: 11442288. DOI: 10.3389/fmolb.2024.1447953.


Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer.

Sai B, Dinakar Y, Kumar H, Jain R, Kesharwani S, Kesharwani S Ther Deliv. 2024; 15(11):871-891.

PMID: 39320858 PMC: 11498026. DOI: 10.1080/20415990.2024.2400044.


Advancements in small interfering RNAs therapy for acute lymphoblastic leukemia: promising results and future perspectives.

Rastgar A, Kheyrandish S, Vahidi M, Heidari R, Ghorbani M Mol Biol Rep. 2024; 51(1):737.

PMID: 38874790 DOI: 10.1007/s11033-024-09650-y.


Reprogramming tendon healing: a guide to novel molecular tools.

Peniche Silva C, Balmayor E, van Griensven M Front Bioeng Biotechnol. 2024; 12:1379773.

PMID: 38784762 PMC: 11112497. DOI: 10.3389/fbioe.2024.1379773.